Smruthi Organics Ltd (SMRUTHIORG) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Smruthi Organics Ltd on NSE and BSE, with an AI summary of each filing.
Intimation regarding receipt of ANVISA Inspection Report
Others (Uncategorized) · 21 Oct 2026, 5:02 pm
Smruthi Organics Receives ANVISA Inspection Report for Unit II API Facility Smruthi Organics received an inspection report from the Brazilian Health Regulatory Agency (ANVISA) for its Unit II facility in Solapur, Maharashtra, following an audit conducted from 7th Jun'26 to 11th Jun'26. The facility was classified as "Complies with Good Manufacturing Practices with Corrective Action" and fulfills conditions for certification regarding the inspected active pharmaceutical ingredient (API). While final GMP certification remains pending receipt, the outcome marks a critical regulatory milestone toward securing market clearance in Brazil.
Approval from CG for appointment of Ms SmruthI eaga as Whoel Time Director
Others (Uncategorized) · 07 Oct 2026, 9:33 pm
Smruthi Organics Receives MCA Approval for Whole-Time Director Appointment Smruthi Organics Limited received approval from the Ministry of Corporate Affairs on 7th Oct'26 for the appointment of Ms. Smruthi Purushotham Eaga as Whole-time Director. The regulatory approval spans a three-year tenure effective from 1st Jun'26 to 31st May'29 under Section 196 and Schedule V of the Companies Act, 2013, following the company's application dated 26th Aug'26.
Scrutinisers Report and Voting Results of AGM
Annual General Meeting · 11 Aug 2026, 12:16 am
Outcome of 37th Annual General Meeting held today i.e 10th August 2026
Annual General Meeting · 10 Aug 2026, 11:06 pm
Un Audited Quarterly Results of the Company for the first quarter ended 30th June 2026
Outcome · 10 Aug 2026, 5:54 pm
Smruthi Organics Reports Strong Q1FY27 Results, Discontinues Formulations Division Smruthi Organics reported strong Q1FY27 results, with Net Profit reaching Rs 287.81 lakh, a significant turnaround from a Rs 109.54 lakh loss YoY and up 169.7% QoQ. Revenue from operations grew 55.4% YoY to Rs 2,930.22 lakh. The Board approved the discontinuance of the Formulations Marketing Division on 13 May'26, which is now classified as a discontinued operation. The core Bulk Drugs and Intermediates (API) division is now the sole operating segment. Basic EPS from continuing operations stood at Rs 2.57 versus Rs (0.91) YoY.
Un Audited Financial Results of the Company for the first quarter ended 30.06.2026
Financial Result · 10 Aug 2026, 5:52 pm
Smruthi Organics Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakhs) ■ Revenue: 2,930 (+55.4% YoY | +0.9% QoQ) ■ EBITDA: 582 (+1837.9% YoY | +49.0% QoQ) ■ EBITDA Margin (%): 19.8 (+1826 bps YoY | +641 bps QoQ) ■ PAT: 288 (Loss to Profit YoY | +169.7% QoQ) ■ EPS (INR): 2.57 (Loss to Profit YoY | +157.0% QoQ) Smruthi Organics Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakhs) Segmental Performance API ■ Revenue: 2,932 (+54.8% YoY | +0.8% QoQ) ■ EBIT: 420 (Loss to Profit YoY | +36.3% QoQ) ■ EBIT Margin (%): 14.3 (Loss to Profit YoY | +373 bps QoQ) Formulation ■ Revenue: 0.0 (-100.0% YoY | -100.0% QoQ) ■ EBIT: -8.8 (-23.0% YoY | +18.7% QoQ) ■ EBIT Margin (%): 0.0 (Loss to Profit YoY | Loss to Profit QoQ)
Smruthi Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Approve and take on record ....
Intimation · 10 Aug 2026, 5:30 am
Smruthi Organics Board Meeting on 10th Aug'26 for Q1FY27 Results Smruthi Organics has scheduled a Board of Directors meeting on 10th Aug'26 to consider and approve the un-audited financial results for the first quarter ended 30th Jun'26. As previously communicated, the company's trading window, which closed on 1st Jul'26, will remain shut until 48 hours after the results are declared.
Notice of 37th Annual General Meeting of Smruthi Organics Ltd
Annual General Meeting · 17 Jul 2026, 10:23 pm
Annual Report of FY 2025-2026
Others (Uncategorized) · 17 Jul 2026, 10:11 pm
Intimation of Record Date
Dividend · 14 May 2026, 6:21 pm
Smruthi Organics Sets Record Date for FY26 Dividend Smruthi Organics (BSE: 540686) has fixed Fri, 31st Jul'26, as the record date for its final dividend for FY25-26. The Board of Directors has recommended a dividend of ₹1.50 per equity share, which translates to a 15% payout on the face value of ₹10 per share. The dividend payment is subject to shareholder approval at the company's 37th Annual General Meeting. This action follows the board meeting outcome intimated on 13th May'26.
AGM Intimation
Annual General Meeting · 13 May 2026, 10:56 pm
Smruthi Organics Announces FY26 Dividend and AGM Date Smruthi Organics' Board has recommended a final dividend of Rs. 1.5 per equity share (15% on a Rs. 10 face value) for the fiscal year ending 31st Mar'26, subject to shareholder approval. The company has set Fri, 31st Jul'26 as the record date for determining dividend eligibility. The book closure period is from 1st Aug'26 to 10th Aug'26. The 37th Annual General Meeting (AGM) will be held on Mon, 10th Aug'26 to approve the dividend and other business items.
Record Date
Dividend · 13 May 2026, 10:34 pm
Smruthi Organics Recommends Rs 1.5/share Dividend for FY26 Smruthi Organics' Board has recommended a dividend of Rs 1.5 per equity share (15% of face value Rs 10) for FY26. The 37th AGM will be held on 10th Aug'26 to approve the dividend. The record date for determining shareholder eligibility is set for 31st Jul'26. The company has also announced a book closure period from 01st Aug'26 to 10th Aug'26 for the purpose of the AGM and dividend payment.
Board approves Dividend
Dividend · 13 May 2026, 8:53 pm
Smruthi Organics Q4FY26 Results, Dividend, & Management Change Smruthi Organics reported Q4FY26 results with Revenue from Operations at Rs. 2,909 lakh and Net Profit at Rs. 107 lakh. For FY26, revenue stood at Rs. 10,197 lakh, with Net Profit of Rs. 343 lakh. The Board declared a dividend of Rs. 1.5 per share (15%) for FY26. Additionally, the Board approved the appointment of Ms. Smruthi Purushotham Eaga as Whole Time Director for three years, effective 01st Jun'26, subject to shareholder approval. Auditors issued an unmodified opinion on the financial results.
Change in management
Change in Management · 13 May 2026, 8:50 pm
Smruthi Organics Appoints Ms. Smruthi Eaga as Whole Time Director Smruthi Organics approved the appointment of Ms. Smruthi Purushotham Eaga as Whole Time Director (Executive) for a 3-year term, effective 01 Jun'26. This changes her designation from Non-Executive Director, pending shareholder approval at the upcoming AGM. Ms. Eaga is the daughter of Chairman & MD Mr. Purushotham Eaga and sister of Joint MD & CFO Mr. Swapnil Eaga. She has handled international marketing for Central and South American markets since FY22 and previously served as a Business Development Executive.
Audited Financial Results for the quarter and financial year ended 31st March 2026
Financial Result · 13 May 2026, 8:44 pm
Smruthi Organics Limited - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakhs) ■ Revenue: 2909 (-23.6% YoY | +30.5% QoQ) ■ EBITDA: 380 (-18.9% YoY | -5.1% QoQ) ■ EBITDA Margin (%): 13.0 (+77 bps YoY | -490 bps QoQ) ■ PAT: 107 (-52.2% YoY | -23.7% QoQ) ■ EPS (INR): 0.93 (-52.3% YoY | -23.8% QoQ) Smruthi Organics Limited - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakhs) Segmental Performance API ■ Revenue: 2909 (-23.5% YoY | +30.7% QoQ) ■ EBIT: 308 (-26.7% YoY | -3.5% QoQ) ■ EBIT Margin (%): 10.6 (-46 bps YoY | -375 bps QoQ) Formulation ■ Revenue: 3.4 (-56.4% YoY | Negative to Positive QoQ) ■ EBIT: -10.9 (+54.1% YoY | +30.0% QoQ) ■ EBIT Margin (%): -317 (-1585 bps YoY | Profit to Loss QoQ)
Outcome of Board meeting of the Company held today i.e 13th May 2026
Outcome · 13 May 2026, 8:38 pm
Smruthi Organics Limited - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakhs) ■ Revenue: 2909 (-23.6% YoY | +30.5% QoQ) ■ EBITDA: 380 (-18.9% YoY | -5.1% QoQ) ■ EBITDA Margin (%): 13.0 (+77 bps YoY | -490 bps QoQ) ■ PAT: 107 (-52.2% YoY | -23.7% QoQ) ■ EPS (INR): 0.93 (-52.3% YoY | -23.8% QoQ) Smruthi Organics Limited - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakhs) Segmental Performance API ■ Revenue: 2909 (-23.5% YoY | +30.7% QoQ) ■ EBIT: 308 (-26.7% YoY | -3.5% QoQ) ■ EBIT Margin (%): 10.6 (-46 bps YoY | -375 bps QoQ) Formulation ■ Revenue: 3.4 (-56.4% YoY | Negative to Positive QoQ) ■ EBIT: -10.9 (+54.1% YoY | +30.0% QoQ) ■ EBIT Margin (%): -317 (-1585 bps YoY | Profit to Loss QoQ)
Smruthi Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2026 ,inter alia, to consider and approve Audited Financial Statements ....
Intimation · 13 May 2026, 5:30 am
Smruthi Organics Board to Review FY26 Results and Dividend on 13th May Smruthi Organics Ltd has scheduled a Board of Directors meeting on 13th May'26. The agenda includes the approval of audited financial results for the quarter and financial year ended 31st Mar'26. The board will also consider and recommend a dividend for FY26, if any. The trading window for designated persons has been closed since 01st Apr'26 and will remain so until 48 hours after the results are declared.
Clarification letter
Others (Uncategorized) · 27 Apr 2026, 10:20 pm
Smruthi Organics Clarifies SEBI (LODR) Compliance Observations In a letter dated 27th Apr'26, Smruthi Organics responded to BSE's compliance observations. The company confirmed it updated website disclosures for Independent Director training programs and hours. It also affirmed that material disclosures under Regulation 30(8) are timely hosted. The company stated Regulation 32 is not applicable as no funds were raised via public, rights, or preferential issues. Additionally, the requirement for a Dividend Distribution Policy does not apply to the company under current regulations.
We are pleased to inform that the Company has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Helathcare (EDQM), Europe for its ....
Others (Uncategorized) · 09 Mar 2026, 4:25 pm
Smruthi Organics Receives European CEP for Amlodipine Besilate Smruthi Organics announced on 09th Mar'26 that it has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its product, Amlodipine Besilate. This certification confirms compliance with European Pharmacopoeia standards, enabling the company to supply the product to pharmaceutical manufacturers in European and other regulated markets that recognize the CEP. The milestone strengthens the company's regulatory portfolio and enhances its expansion opportunities in key international territories.
Receipt of "Attestation of Inspection" from EDQM
Others (Uncategorized) · 04 Mar 2026, 1:11 pm
Smruthi Organics Receives EU GMP Attestation for Solapur API Facility Smruthi Organics received an "Attestation of Inspection" from Europe's EDQM on 04 Mar'26 for its Solapur API facility (Unit II), confirming compliance with EU GMP requirements. The successful inspection, conducted from 27 Aug'25 to 29 Aug'25, specifically covers Amlodipine Besilate under the CEP framework. This positive regulatory outcome is expected to strengthen its position in European markets, support business expansion, and enhance export opportunities. The formal Certificate of Suitability (CEP) is currently under final administrative processing by the EDQM.
Financial Results
Financial Result · 13 Feb 2026, 4:52 pm
Smruthi Organics Q3 FY26 Results Miss Estimates Amid Revenue Decline Smruthi Organics reported weak Q3 FY26 results with net profit falling 32.0% QoQ and 5.7% YoY to ₹139.79 lakhs. Revenue from operations declined sharply by 28.8% YoY to ₹2229.11 lakhs. The company recognized an exceptional expense of ₹45.17 lakhs due to the impact of new labour codes. Profit before tax stood at ₹163.26 lakhs, down 28.7% YoY. The core API segment revenue fell 28.7% YoY to ₹2225.95 lakhs. Basic EPS for the quarter dropped to ₹1.22 from ₹1.80 last quarter and ₹1.29 YoY.
Outcome of board meeting held on Friday, 13th February 2026
Outcome · 13 Feb 2026, 4:48 pm
Smruthi Organics Limited - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakhs) ■ Revenue: 2229 (-28.7% YoY | -29.4% QoQ) ■ EBITDA: 400 (-3.9% YoY | -20.1% QoQ) ■ EBITDA Margin (%): 18.0 (+463 bps YoY | +209 bps QoQ) ■ PAT: 140 (-5.6% YoY | -32.0% QoQ) ■ EPS (INR): 1.22 (-5.4% YoY | -32.2% QoQ) Smruthi Organics Limited - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakhs) Segmental Performance API ■ Revenue: 2226 (-28.7% YoY | -29.4% QoQ) ■ EBIT: 319 (-13.1% YoY | -21.9% QoQ) ■ EBIT Margin (%): 14.3 (+257 bps YoY | +137 bps QoQ) Formulation ■ Revenue: -0.6 (Positive to Negative YoY | Positive to Negative QoQ) ■ EBIT: -15.5 (+17.2% YoY | -62.2% QoQ) ■ EBIT Margin (%): 2766 (Loss to Profit YoY | Loss to Profit QoQ)
Smruthi Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1) ....
Intimation · 13 Feb 2026, 5:30 am
Smruthi Organics Board Meeting on 13th Feb'26 for Q3FY26 Results Smruthi Organics Ltd has scheduled a Board of Directors meeting for 13th Feb'26 to consider and approve the un-audited financial results for the third quarter ending 31st Dec'25. The company's trading window, which closed on 1st Jan'26, will remain shut until 48 hours after the results are declared.
Financial Results
Financial Result · 11 Nov 2025, 4:18 pm
Quarterly Results for second quarter and half year ended 30th September, 2025
Outcome · 11 Nov 2025, 4:15 pm